Summary
67 / 100 · Bulios Score
What speaks for it
- It bought back its own shares for $59.5M in the last fiscal year, 3.0% of its market value.
What to watch
- Revenue fell by 48% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 3.1 USD is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 7.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 10% a year over 5 years. Over the last 3 years it fell by 48% a year. For the next fiscal year analysts expect revenue to grow by 0.1%.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 91 USD
- Research and development 1.8 USD
- Sales and administration 3.9 USD
- Taxes and other 17 USD
- Net profit 3.1 USD
Net profit, industry median (Financial - Capital Markets) 20 USD
Out of every 100 USD of revenue, 3.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
Banks and insurers work with their customers' money, so their debt is judged differently; see the health section for their capital figures.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $43.25 is 77% above today's price. 64% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.